Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes
Posted innews OB/GYN & Women's Health Oncology

Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes

A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-endometrioid tumors. The findings underscore the need for comprehensive molecular profiling to guide personalized treatment strategies.
Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location
Posted innews OB/GYN & Women's Health Oncology

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recurrence location relative to previous radiotherapy fields.
Prioritizing Return of Value: A Roadmap to Enhancing Biobanking Participation Among Black Women with Endometrial Cancer
Posted innews OB/GYN & Women’s Health Oncology

Prioritizing Return of Value: A Roadmap to Enhancing Biobanking Participation Among Black Women with Endometrial Cancer

This community-engaged mixed-methods study identifies critical Return of Value (ROV) elements, such as genetic insights and community health benefits, to improve biobanking engagement among Black women with endometrial cancer, offering 14 actionable recommendations for equitable translational research.
Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial
Posted inOB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.
Fertility-Preserving Hormonal Therapy vs Hysterectomy in Early-Stage Endometrial Cancer: Survival Outcomes and Clinical Implications
Posted innews OB/GYN & Women's Health Oncology Specialties

Fertility-Preserving Hormonal Therapy vs Hysterectomy in Early-Stage Endometrial Cancer: Survival Outcomes and Clinical Implications

This analysis compares survival in young women with early-stage endometrial cancer treated with fertility-preserving hormonal therapy versus hysterectomy, highlighting survival equivalence in women under 40 years and increased mortality risk in older patients undergoing hormonal therapy.